Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. (EVGN) shareholder Leon Recanati filed Amendment No. 2 to a Schedule 13D updating how his recent share purchases were executed and confirming his ownership position. Recanati beneficially owns 1,354,836 ordinary shares, including options, representing 8.6% of the outstanding ordinary shares based on 15,801,407 shares outstanding as of July 27, 2026.
The amendment clarifies that he bought 800,000 shares on August 4, 2026 at a weighted average price of $0.50 per share and 460,000 shares on August 11, 2026 at $0.635 per share, for total consideration of approximately $692,100. These purchases were executed as block trades under Evogene's at-the-market offering facility, for which A.G.P./Alliance Global Partners acts as sales agent, using Recanati’s personal funds. Before the August 4 purchases, he held 83,886 shares directly, excluding option shares.
Evogene Ltd. (EVGN) reports that it held its annual general meeting of shareholders on September 4, 2026, with a quorum present and shareholder voting conducted on proposals previously described in its July 31, 2026 proxy materials. Proposals 1(a) and 2–4 were approved by the requisite shareholder vote.
Effective at the end of the meeting, Evogene’s board of directors consists of Nir Nimrodi, Adrian Percy, Leon Y. Recanati, Dan Falk, Yael Margolin, Yoshinori Oikawa, and Ofer Haviv, who also serves as CEO and President. The information in this report is incorporated by reference into Evogene’s existing Form F-3 and Form S-8 registration statements.
Evogene Ltd. (EVGN) has an updated Schedule 13D/A showing that a group led by L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., together with Kfir Silberman and Ron Yair Peled, beneficially owns 3,057,488 ordinary shares, representing 19.35% of Evogene’s ordinary shares, based on 15,801,407 shares outstanding as of July 27, 2026. Pure Capital has sole dispositive power over 2,557,488 shares, while Invest Pro has sole dispositive power over 500,000 shares, and all reporting persons share voting power over the full 3,057,488 shares.
This Amendment No. 5 reports that on August 28, 2026, the reporting persons disseminated a shareholder communication titled “Response of L.I.A. Pure Capital and Invest-Pro to Evogene's August 25, 2026 Press Release,” expressing their views on Evogene’s performance, governance and board composition and encouraging shareholders to support their nominees to Evogene’s board at the upcoming annual meeting. The communication is filed as Exhibit 8.
Evogene Ltd. (EVGN) reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share in an open-market or private transaction. Following this buy, Tarcic holds 1,129 Ordinary Shares directly and has stock options covering 40,000 Ordinary Shares at an exercise price of $2.305 per share, expiring November 20, 2034. The option position was unchanged and is disclosed for informational purposes, with vesting over four years from the November 20, 2024 grant date.
Evogene Ltd. reported first half 2026 and second quarter 2026 results alongside a major strategic transformation into a lean, AI-driven computational chemistry company. The workforce was reduced from 117 employees in December 2024 to 38 in August 2026, operations were streamlined, and non-core activities (Lavie Bio, Biomica, Casterra outside Brazil) were monetized or wound down.
For the six months ended June 30, 2026, Evogene generated $681 thousand in revenues versus $2,877 thousand a year earlier, with a loss attributable to equity holders of $7,638 thousand and operating loss of $5,387 thousand. Cash and cash equivalents were $9,316 thousand at June 30, 2026, and the company expects full-year 2026 cash usage of approximately $8.5–9.5 million, down from approximately $14.4 million in 2025 and $20.5 million in 2024. Since the beginning of 2025, it has raised approximately $11.1 million in new capital and received dividends of approximately $2.9 million from Lavie Bio and $1.35 million from Biomica.
Evogene expanded its ChemPass AI platform, increasing its virtual chemical space from approximately 36 billion to approximately 110 billion molecules, added autonomous AI Agents via a second agreement with Google Cloud, and introduced an Antifungal Potency Predictor model. The pharma division now has six active drug development collaborations, with some programs already past Hit Identification and an internal program progressing into Lead Optimization, while the agriculture program targeting Septoria nears completion of Lead Optimization.
Armistice Capital, LLC and Steven Boyd report their ownership of Evogene Ltd. ordinary shares on an amended Schedule 13G. They report beneficial ownership of 713,539 shares, representing 4.99% of the class.
The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager with voting and investment power under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these securities. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported. The Master Fund has the right to receive dividends and sale proceeds from the securities.
Evogene Ltd. shareholders led by L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. report increased ownership following open-market purchases of 533,088 American Depositary Shares (ADSs) by Pure Capital using working capital.
After these transactions, the reporting persons collectively report beneficial ownership of 3,057,488 Ordinary Share equivalents, representing 19.35% of Evogene’s outstanding share capital, based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026. Pure Capital has sole dispositive power over 2,501,388 ADSs and 56,100 Ordinary Shares (about 16.19% of the company), while Invest Pro has sole dispositive power over 500,000 ADSs (about 3.16%). Voting power over 3,001,388 ADSs and 56,100 Ordinary Shares is shared under an oral voting agreement. Kfir Silberman and Ron Yair Peled may be deemed beneficial owners through their control of Pure Capital and Invest Pro, respectively, but each disclaims beneficial ownership beyond their pecuniary interest.
Evogene Ltd. director Leon Recanati reports updated beneficial ownership of the company’s ordinary shares. As of this amendment, he beneficially owns 1,354,836 Ordinary Shares, representing 8.6% of Evogene’s outstanding Ordinary Shares, based on 15,801,407 shares outstanding as of July 27, 2026. This total includes 1,343,886 shares held directly and 10,950 shares underlying options that are currently exercisable or exercisable within 60 days of August 11, 2026.
On August 11, 2026, Recanati purchased an additional 460,000 Ordinary Shares in open market transactions at a price of $0.635 per share, for aggregate consideration of $292,100, funded with his personal funds. He has sole voting and dispositive power over all shares he beneficially owns and reports no agreements with others regarding Evogene securities.
Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction. Following this trade, he directly holds 1,343,886 Ordinary Shares. The filing also lists several existing stock option awards over Ordinary Shares at exercise prices ranging from $1.29 to $54.32 with expirations between 2027 and 2035; per the footnotes, these option rows reflect holdings only and no new transactions.